Save this page
Save this page

My Saved Pages

  • Saved page.

My Saved Courses

  • Saved page.
Reset

Recently visited

  • Saved page.

Development of novel tumour-targeted nanomedicines for cancer therapy

The student will have the opportunity to learn a wide range of multidisciplinary techniques: synthesis and characterization of the nanomedicines, cell culture, in vitro analysis techniques (cytotoxicity assay, confocal microscopy) and in vivo analysis

Number of places

1

Opens

20 February 2018

Deadline

31 October 2018

Duration

36 Months

Eligibility

2:1 UK Honours degree or overseas equivalent.

Project Details

The possibility of using non-viral gene delivery systems for the treatment of cancer is currently limited by their failure to specifically reach tumours after intravenous administration, without secondary effects on normal tissues. We have recently demonstrated that the intravenous administration of therapeutic DNA complexed to polypropylenimine dendrimer bearing transferrin, whose receptors are overexpressed on most cancers, led to a rapid and sustained tumour regression over one month, with complete disappearance of 90% of the tested tumours and regression of the remaining ones for the cancer model tested. These results are highly important, as there is currently no gene medicine commercially available for the intravenous treatment of cancer.

Building on the promising results already obtained, the proposed project aims to develop novel tumour-targeted nanomedicines and to evaluate their targeting and therapeutic efficacy on cancers. Specifically, the key objectives are:

        - the preparation and characterization of novel tumour-targeting delivery systems

        - the evaluation of the tumour delivery and therapeutic efficacy of these systems in vitro and in vivo.

Funding Details

Applicant's will need to find their own source of funding for this project

Supervisor

Dr Christine Dufes

https://www.strath.ac.uk/staff/duf%C3%A8schristinedr/

Further information

References

 

S. Koppu, Y.J. Oh, R. Edrada-Ebel, D.R. Blatchford, L. Tetley, R. J. Tate, C. Dufès, Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA, Journal of Controlled Release, 143 (2010) 215-221 (with cover and editorial)

 

- H. Aldawsari, R. Edrada-Ebel, D.R. Blatchford, R. J. Tate, L. Tetley, C. Dufès, Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplex, Biomaterials, 32 (2011) 5889-5899

 

- M. Al Robaian, K.Y. Chiam, D.R. Blatchford, C. Dufès, Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes encoding TNF-α, TRAIL and interleukin-12 on prostate carcinomas, Nanomedicine, 9(4) (2014) 421-434

 

- L. Y. Lim, P.Y. Koh, S. Somani, M. Al Robaian, R. Karim, Y.L. Yean, J. Mitchell, R.J. Tate, R. Edrada-Ebel, D.R. Blatchford, M. Mullin, C. Dufès, Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes, Nanomedicine : Nanotechnology, Biology and Medicine, 11 (2015) 1445-1454

Contact us

Any enquiries relating to this project please contact Dr Christine Dufes - c.dufes@strath.ac.uk

How to apply

Information on How to Apply can be found using the following link 

https://www.strath.ac.uk/courses/research/pharmacybiomedicalsciences/

Development of novel tumour-targeted nanomedicines entrapping nutraceuticals for cancer therapy

The student will have the opportunity to learn a wide range of multidisciplinary techniques: preparation and characterization of the nanomedicines, cell culture, in vitro analysis techniques (cytotoxicity assay, confocal microscopy) and in vivo analysis.

Number of places

1

Opens

20 February 2018

Deadline

31 October 2018

Eligibility

2:1 UK Honours degree or overseas equivalent.

Project Details

The therapeutic potential of natural products with promising anti-cancer properties (nutraceuticals), such as the vitamin E extract tocotrienol and the green tea extract epigallocatechin gallate (EGCG), is limited by the failure of these drugs to specifically reach tumours after intravenous administration, without secondary effects on normal tissues. We have recently demonstrated that the intravenous administration of novel tumour-targeted vesicles entrapping either tocotrienol or EGCG led to tumour regression, with the complete disappearance of 40% of the tested melanoma tumours, contrarily to that observed with controls. It was the first time that intravenously administered formulations of tocotrienol and EGCG were shown to result to complete tumour suppression. These results were highly promising, but still require to be optimized.

Building on the promising results already obtained, the proposed project aims to develop novel tumour-targeted nanomedicines entrapping other promising nutraceuticals, and to evaluate their targeting and therapeutic efficacy on cancers. Specifically, the key objectives are:

        - the preparation and characterization of novel tumour-targeting delivery systems

        - the evaluation of the tumour delivery and therapeutic efficacy of these systems in vitro and in vivo.

Funding Details

Applicant's will need to find their own source of funding for this project

Supervisor

Dr Christine Dufes - https://www.strath.ac.uk/staff/duf%C3%A8schristinedr/

Contact us

Dr Christine Dufes - c.dufes@strath.ac.uk

How to apply

Details on How To Apply can be found using the following link

https://www.strath.ac.uk/courses/research/pharmacybiomedicalsciences/

Development of novel tumour-targeted, albumin-based nanomedicines for cancer therapy

The student will have the opportunity to learn a wide range of multidisciplinary techniques: synthesis and characterization of the nanomedicines, cell culture, in vitro analysis techniques (cytotoxicity assay, confocal microscopy, flow cytometry) and in vivo analysis.

Number of places

1

Opens

20 February 2018

Deadline

31 October 2018

Duration

36 Months

Eligibility

2:1 UK Honours degree or overseas equivalent.

Project Details

The possibility of using non-viral gene delivery systems for the treatment of cancer is currently limited by their failure to specifically reach tumours after intravenous administration, without secondary effects on normal tissues. We have recently demonstrated that the intravenous administration of therapeutic DNA complexed to polypropylenimine dendrimer bearing transferrin, whose receptors are overexpressed on most cancers, led to a rapid and sustained tumour regression over one month, with complete disappearance of 90% of the tested tumours and regression of the remaining ones for the cancer model tested. These results are highly important, as there is currently no gene medicine commercially available for the intravenous treatment of cancer.

In this project, we would like to develop a similar delivery approach using albumin, the main protein of plasma. Its high stability in pH (from 4 to 9) and heat (<60 °C), preferential uptake in tumour and inflamed tissue, biodegradability, low toxicity, immunogenicity and suitable blood circulation with a half-time of 19 days makes albumin an ideal material as a delivery carrier. In addition, albumin has been known to be a suitable agent for gene therapy since it avoids undesired interaction with serum, which often occurs after intravenous injection of transfection complexes.

The proposed project aims to develop novel tumour-targeted, albumin-based nanomedicines and to evaluate their targeting and therapeutic efficacy on cancers. Specifically, the key objectives are:

        - the preparation and characterization of novel tumour-targeting, albumin-based delivery systems

        - the evaluation of the tumour delivery and therapeutic efficacy of these systems in vitro and in vivo.

Funding Details

Applicant's will need to find their own source of funding for this project

Supervisor

Dr Christine Dufes - https://www.strath.ac.uk/staff/duf%C3%A8schristinedr/

Contact us

Dr Christine Dufes - c.dufes@strath.ac.uk

How to apply

Information on How To Apply can be found using the following link:

https://www.strath.ac.uk/courses/research/pharmacybiomedicalsciences/